Lantheus Holdings Inc. (LNTH) Downgraded by Zacks Investment Research
According to Zacks, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States. “
LNTH has been the topic of a number of other reports. Credit Suisse Group AG assumed coverage on shares of Lantheus Holdings in a research note on Friday, September 23rd. They issued a neutral rating and a $8.00 price objective on the stock. Jefferies Group reaffirmed a buy rating on shares of Lantheus Holdings in a research note on Friday, August 5th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $7.40.
Shares of Lantheus Holdings (NASDAQ:LNTH) traded up 1.558% on Wednesday, hitting $8.409. 22,390 shares of the company’s stock were exchanged. The firm has a market cap of $255.52 million, a P/E ratio of 9.491 and a beta of 0.47. The stock’s 50 day moving average is $8.45 and its 200 day moving average is $4.47. Lantheus Holdings has a 12 month low of $1.76 and a 12 month high of $10.10.
Lantheus Holdings (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, August 4th. The company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.18. Lantheus Holdings had a net margin of 9.00% and a negative return on equity of 11.75%. The firm had revenue of $78 million for the quarter, compared to analyst estimates of $72.66 million. On average, equities analysts predict that Lantheus Holdings will post $0.55 earnings per share for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its position in Lantheus Holdings by 6,447.0% in the second quarter. BlackRock Inc. now owns 28,021 shares of the company’s stock worth $103,000 after buying an additional 27,593 shares during the last quarter. Acrospire Investment Management LLC bought a new stake in shares of Lantheus Holdings during the second quarter valued at approximately $107,000. TFS Capital LLC bought a new stake in shares of Lantheus Holdings during the second quarter valued at approximately $156,000. Oxford Asset Management bought a new stake in shares of Lantheus Holdings during the second quarter valued at approximately $158,000. Finally, Paloma Partners Management Co bought a new stake in shares of Lantheus Holdings during the second quarter valued at approximately $179,000. 30.15% of the stock is currently owned by institutional investors.
Lantheus Holdings Company Profile
Lantheus Holdings, Inc develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.